Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Mazapertine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.91 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.91 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.91 |
| ▸ | HTR1A | P08908 | 1/20 | 0.91 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.91 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.91 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mazapertine SCHEMBL1649526 | 1.00 | HTR1A (0.91) | HTR1ADRD2ADRA1DHTR1BADRA1A | |
| Mazapertine SCHEMBL6013382 | 1.00 | HTR1A (0.91) | HTR1ADRD2ADRA1DHTR1BADRA1A | |
| Mazapertine SCHEMBL636631 | 0.95 | HTR1A (1.00) | HTR1ADRD2ADRA1DHTR1BADRA1A | |
| SCHEMBL13533242 | 0.95 | HTR1A (1.00) | HTR1ADRD2ADRA1DHTR1BADRA1A | |
| Hydrochloric Acid SCHEMBL7644692 | 0.94 | HTR1A (0.98) | HTR1ADRD2ADRA1DHTR1BADRA1A | |
| Mazapertine SCHEMBL7643633 | 0.94 | HTR1A (0.98) | HTR1ADRD2ADRA1DHTR1BADRA1A | |
| SCHEMBL9540919 | 0.86 | ADRA1D (0.82) | HTR1ADRD2ADRA1DHTR1BADRA1A | |
| Hydrochloric Acid SCHEMBL7647394 | 0.85 | HTR1A (0.80) | HTR1ADRD2ADRA1DHTR1BADRA1A | |
| Oxalic Acid SCHEMBL7648376 | 0.85 | ADRA1D (0.77) | HTR1ADRD2ADRA1DHTR1BADRA1A | |
| SCHEMBL9539641 | 0.85 | HTR1A (0.80) | HTR1ADRD2ADRA1DHTR1BADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED) (IE) | 2015-11-12 | — | — | US | claimed |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | claimed |
| WO-2011126937-A1 | TARGETED INTRACELLULAR DELIVERY OF OLIGONUCLEOTIDES VIA CONJUGATION WITH SMALL MOLECULE LIGANDS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2011-10-13 | — | — | WO | claimed |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | claimed |
| US-20080103155-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | SPROUT PHARMACEUTICALS, INC. | 2008-05-01 | — | — | US | claimed |
| CN-1946404-A | Pharmaceutical compositions for the treatment of sexual disorders II | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-04-11 | — | — | CN | claimed |
| EP-1740181-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SEXUAL DISORDERS II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-10 | — | — | EP | claimed |
| US-20050245539-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | US | claimed |
| WO-2005102342-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SEXUAL DISORDERS II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | claimed |
| WO-2005055920-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF PSYCHIATRIC DISORDERS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2005-06-23 | — | — | WO | claimed |
| EP-1044023-B1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | LUITPOLD PHARM INC (US) | 2005-05-25 | — | — | EP | claimed |
| WO-2004103263-A2 | DOPAMINE AND AGONISTS AND ANTAGONISTS THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISEASES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2004-12-02 | — | — | WO | claimed |
| EP-0563345-B1 | NOVEL 4-ARYLPIPERAZINES AND 4-ARYLPIPERIDINES | MCNEILAB INC (US) | 2002-07-03 | — | — | EP | claimed |
| US-6197764-B1 | COMPLEX WITH FATTY ACID; THERAPY FOR PSYCHOLOGICAL DISORDERS | PROTARGA, INC. | 2001-03-06 | — | — | US | claimed |
| EP-1044023-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | Protarga Inc. (US) | 2000-10-18 | — | — | EP | claimed |
| US-5955459-A | Fatty acid-antipsychotic compositions and uses thereof | NEUROMEDICA, INC. (US) | 1999-09-21 | — | — | US | claimed |
| WO-1999026661-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | PROTARGA INC. (US) | 1999-06-03 | — | — | WO | claimed |
| US-5569659-A | ANTIPSYCHOTIC AGENT | MCNEILAB, INC. (US) | 1996-10-29 | — | — | US | claimed |
| EP-0563345-A1 | NOVEL 4-ARYLPIPERAZINES AND 4-ARYLPIPERIDINES | MCNEILAB, INC. (US) | 1993-10-06 | — | — | EP | claimed |
| WO-1993004682-A1 | NOVEL 4-ARYLPIPERAZINES AND 4-ARYLPIPERIDINES | MCNEILAB, INC. (US) | 1993-03-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103155-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | FLNB, FLNA, FGB | DRD2 38/4885HTR1B 8/4885DRD3 164/4885 |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | DRD2 38/4885HTR1B 8/4885DRD3 164/4885 |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | DRD2 38/4885HTR1B 8/4885DRD3 164/4885 |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | DRD2 38/4885HTR1B 8/4885DRD3 164/4885 |
| US-20050245539-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | FLNB, FLNA, FGB | DRD2 38/4885HTR1B 8/4885DRD3 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.